| Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses. | |
| | |
MedLine Citation:
|
PMID: 22305678 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Infections with Streptococcus pneumoniae (pneumococcus) are a cause of significant child mortality. Pneumococcal glycoconjugate vaccines are expensive and provide limited serotype coverage. The 23-valent pneumococcal polysaccharide vaccine (Pneumovax) might provide wider serotype coverage but is reported to be weakly immunogenic in children less than 2 years of age. We have previously reported that Pneumovax administered to healthy 12-month-old Fijian infants elicits significant serotype-specific IgG responses. However, the functional capacity of these responses in 12-month-old infants is not known. OBJECTIVE: We sought to assess the functional, serotype-specific immune response of 12-month-old infants after immunization with Pneumovax. METHODS: Functional responses of 12-month-old infants were assessed by using the opsonophagocytic and antibody avidity assay against 8 serotypes and 23 serotypes, respectively. RESULTS: Seventy-one percent of infants produced strong opsonophagocytic activity against 4 of 8 serotypes, and 30% produced high-avidity serotype-specific IgG antibodies to 10 of 23 serotypes at 2 weeks after Pneumovax. Responses were protective for most serotypes that cause disease in Western countries, whereas responses to most of the epidemiologically relevant serotypes for developing countries were low. CONCLUSION: This is the first comprehensive study evaluating the functional antibody response to Pneumovax in 12-month-old infants. Pneumovax induced functional antibody responses to several serotypes causing disease in Western countries but induced poorer responses to serotypes that are responsible for the majority of disease in developing countries. Pneumovax might be of benefit in some populations, but further studies are required before this can be recommended in developing countries. |
| | |
Authors:
|
Paul V Licciardi; Anne Balloch; Fiona M Russell; Robert L Burton; Jisheng Lin; Moon H Nahm; Edward K Mulholland; Mimi L K Tang |
Related Documents
:
|
21788658 - Overcoming barriers to investigating mother-infant interactions in the first two hours ... 22805468 - Fish oil supplementation in early infancy modulates developing infant immune responses. 16613618 - Migration as a determinant of marriage pattern: preliminary report on consanguinity amo... 22883708 - Prosody signals the emergence of intentional communication in the first year of life: e... 7472938 - Enteral feeding increases sepsis in infants with short bowel syndrome. 16537218 - Mortality due to injuries in maputo city, mozambique. |
Publication Detail:
|
Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2012-02-02 |
Journal Detail:
|
Title: The Journal of allergy and clinical immunology Volume: 129 ISSN: 1097-6825 ISO Abbreviation: J. Allergy Clin. Immunol. Publication Date: 2012 Mar |
Date Detail:
|
Created Date: 2012-03-05 Completed Date: 2012-07-06 Revised Date: 2013-05-20 |
Medline Journal Info:
|
Nlm Unique ID: 1275002 Medline TA: J Allergy Clin Immunol Country: United States |
Other Details:
|
Languages: eng Pagination: 794-800.e2 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright © 2012 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved. |
Affiliation:
|
Pneumococcal Laboratory, Murdoch Childrens Research Institute, Melbourne, Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Bacterial
/
blood,
immunology Developing Countries* Epitopes Female Fiji Follow-Up Studies Humans Immunization Immunoglobulin G / blood, immunology Infant Male Pneumococcal Infections / epidemiology, immunology*, prevention & control Pneumococcal Vaccines / administration & dosage* Streptococcal Vaccines / administration & dosage* Streptococcus pneumoniae / immunology* |
| Grant Support | |
ID/Acronym/Agency:
|
2 U01 AI052337-05/AI/NIAID NIH HHS; AI-30021/AI/NIAID NIH HHS; U01 AI052337-05/AI/NIAID NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Bacterial; 0/Epitopes; 0/Immunoglobulin G; 0/Pneumococcal Vaccines; 0/Streptococcal Vaccines |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparing ion conductance recordings of synthetic lipid bilayers with cell membranes containing TRP ...
Next Document: Advances in upper airway diseases and allergen immunotherapy in 2011.